Sir,

We thank M. D. Al-Mendalawi.\[[@ref1]\] for their interest in our case report\[[@ref2]\] and the insightful comments. We agree that association of malaria and hemolytic uremic syndrome-thrombotic thrombocytopenia purpura (HUS-TTP) may not be causal and only a few cases have been described hitherto. However, ADAMTS13 activity and antigen levels have been reported to be reduced in patients with falciparum as well as vivax malaria.\[[@ref3]\] This evidence of endothelial injury in malarial infections is intriguing and needs to be explored. Furthermore, given the vivax malaria increasingly being reported as a cause of severe malaria,\[[@ref4]\] it will be interesting to study what proportion of them have HUS-TTP.

Thrombotic microangiopathy is a histologic description that is characteristic of several diverse disorders, such as malignant hypertension and scleroderma, as well as TTP and HUS.\[[@ref5][@ref6]\] When the patients with microangiopathic hemolytic anemia and thrombocytopenia are initially evaluated, the comprehensive term TTP-HUS can probably be the best one to describe the clinical entity seen in our patient.

We agree that a complete evaluation including assessment of ADAMTS13 activity and genetic and autoimmune tests to identify a complement-related defect is required, which could not be done in our case. In absence of such a detailed evaluation, there remains a possibility of presence of underlying complement disorder where HUS was triggered by malarial infection. Infections, including diarrhea, are known as a trigger to develop HUS in patients having complement dysregulation.\[[@ref7][@ref8]\]
